RSV+hMPV±PIV3 combination vaccine | Search

Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

51,431 results for “RSV+hMPV±PIV3 combination vaccine”

Trials

View all 35268 →

Active, not recruiting

Study of an RSV-hMPV-PIV3 Trivalent Vaccine Candidate VXB-251 in Older Adults

240 participants · First posted Dec 19, 2025

Active, not recruiting

Study of a Respiratory Syncytial Virus/Human Metapneumovirus/Parainfluenza Virus Type 3 Vaccine Candidate in Adults Aged 60 Years and Older

390 participants · First posted Sep 19, 2024

Study to Evaluate the Safety and Immune Response of an Investigational Vaccine for the Prevention of RSV (Respiratory Syncytial Virus) and (hMPV) Human Metapneumovirus Infection in Participants Aged 60 to 75 Years

385 participants · First posted Sep 3, 2024

Drugs

View all 6190 →

RSV-hMPV vaccine (RSV Infection/hMPV Infection)

mRNA-1365

RSV/hMPV mRNA Vaccine (Sanofi)

Organizations

View all 119 →

RSV Therapeutics LLC

COMBINATION THERAPEUTICS AUSTRALIA PTY LTD

Australia

AIM VACCINE

China

News

View all 9854 →

Clover Biopharmaceuticals Appoints Nicholas Jackson as President of Global R&D to Advance RSV Combination Vaccine Development

Clover Reports Positive Phase 2 Data for RSV + hMPV ± PIV3 Combination Vaccines in Older Adults

Clover Biopharmaceuticals Reports Positive Phase I Data for First-in-Class RSV-hMPV-PIV3 Combination Vaccines

Page 1 of 5144